Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas

Toulemonde, E.; Chevret, Sylvie; Battistella, Maxime; Neidhardt, Ève-Marie; Nardin, Charlée; Du, F Le; Meyer, Nicolas; Véron, M; Gambotti, Laëtitia; Lamrani-Ghaouti, Assia; Jamme, Philippe; Chaffaut, Cendrine; Pontville, M De; Sâada-Bouzid, Esma; Beylot‐Barry, M.; Simon, C; Jouary, Thomas; Marabelle, Aurélien; Mortier, Laurent

doi:10.1007/s00262-023-03449-9

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vismodegib, an FDA-approved sonic hedgehog pathway inhibitor indicated for locally advanced or metastatic BCC, has exhibited promising results in the treatment of advanced TBC with better tolerability than sunitinib [ 17 , 20 , 22 ]. A recent phase II study with nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, also demonstrated promising results with an 80% one-year survival rate and 54.5% progression-free survival at six months in 11 patients with advanced TBC [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Trichoblastic Carcinoma in the Glabella Treated With Mohs Micrographic Surgery

Park,

Crasto,

Kubicki

et al. 2024

Cureus

View full text Add to dashboard Cite

Trichoblastic carcinoma (TBC) is a rare adnexal neoplasm of follicular germ cell differentiation with the potential for local invasion and metastasis. Histologic features of trichoblastic carcinoma have significant overlap with trichoblastoma and basal cell carcinoma (BCC), making diagnosis difficult in some cases. Treatment strategies are not well defined and include surgical excision for localized tumors and systemic therapies for metastatic disease. We present a case of trichoblastic carcinoma clinically resembling a benign cyst that was ultimately treated with Mohs micrographic surgery (MMS).

show abstract